We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Allergan on Wednesday announced topline results from the Phase III RAP-MD-01, RAP-MD-02 and RAP-MD-03 studies of the major depressive disorder (MDD) drug candidate rapastinel, saying treatment arms did not differentiate from placebo on the primary and key